GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRIGRI Bio(GRI) Newsfilter·2024-05-22 21:15

Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to watch the "What This Means" segment LA JOLLA, CA, May 22, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseas ...